G6PD
Glucose-6-phosphate 1-dehydrogenase
Also known as: G6PD_HUMAN, G6PD1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P11413
- Gene
- G6PD
- Ensembl
- ENSG00000160211
- Chromosome
- X
- Canonical length
- 515 aa
- Protein class
- Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Centriolar satellite,Cytosol
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
This gene encodes glucose-6-phosphate dehydrogenase. This protein is a cytosolic enzyme encoded by a housekeeping X-linked gene whose main function is to produce NADPH, a key electron donor in the defense against oxidizing agents and in reductive biosynthetic reactions. G6PD is remarkable for its genetic diversity. Many variants of G6PD, mostly produced from missense mutations, have been described with wide ranging levels of enzyme activity and associated clinical symptoms. G6PD deficiency may cause neonatal jaundice, acute hemolysis, or severe chronic non-spherocytic hemolytic anemia. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
515 residues, UniProt reviewed canonical sequence.
>P11413|G6PD
1 MAEQVALSRT QVCGILREEL FQGDAFHQSD THIFIIMGAS GDLAKKKIYP TIWWLFRDGL
61 LPENTFIVGY ARSRLTVADI RKQSEPFFKA TPEEKLKLED FFARNSYVAG QYDDAASYQR
121 LNSHMNALHL GSQANRLFYL ALPPTVYEAV TKNIHESCMS QIGWNRIIVE KPFGRDLQSS
181 DRLSNHISSL FREDQIYRID HYLGKEMVQN LMVLRFANRI FGPIWNRDNI ACVILTFKEP
241 FGTEGRGGYF DEFGIIRDVM QNHLLQMLCL VAMEKPASTN SDDVRDEKVK VLKCISEVQA
301 NNVVLGQYVG NPDGEGEATK GYLDDPTVPR GSTTATFAAV VLYVENERWD GVPFILRCGK
361 ALNERKAEVR LQFHDVAGDI FHQQCKRNEL VIRVQPNEAV YTKMMTKKPG MFFNPEESEL
421 DLTYGNRYKN VKLPDAYERL ILDVFCGSQM HFVRSDELRE AWRIFTPLLH QIELEKPKPI
481 PYIYGSRGPT EADELMKRVG FQYEGTYKWV NPHKLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against G6PD can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 79 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 79 nTPM
- testis: 75 nTPM
- esophagus: 69 nTPM
- adrenal gland: 61 nTPM
- blood vessel: 49 nTPM
- pituitary gland: 48 nTPM
Single-cell type
- oocytes: 193 nCPM
- esophageal suprabasal cells: 164 nCPM
- platelets: 160 nCPM
- neutrophil progenitors: 148 nCPM
- neutrophils: 141 nCPM
- megakaryocytes: 136 nCPM
Immune cell
- eosinophil: 383 nTPM
- basophil: 154 nTPM
- neutrophil: 127 nTPM
- classical monocyte: 76 nTPM
- NK-cell: 66 nTPM
- total PBMC: 65 nTPM
Brain region
- thalamus: 41 nTPM
- medulla oblongata: 39 nTPM
- pons: 36 nTPM
- cerebral cortex: 33 nTPM
- hypothalamus: 33 nTPM
- midbrain: 32 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about G6PD.
Disease | AllUniProt
Conditions G6PD is implicated in, by any mechanism.
- Anemia, congenital, non-spherocytic hemolytic, 1 (CNSHA1) MIM:300908
Disease | GeneticClinVar
230 pathogenic / likely-pathogenic of 875 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Anemia, nonspherocytic hemolytic, due to G6PD deficiency
- Malaria, susceptibility to
- G6PD deficiency
- Inborn genetic diseases
- G6PD-related disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.32
- gnomAD pLI
- 0.97
- gnomAD missense Z
- 2
- DepMap mean gene effect
- -0.15
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cellular response to oxidative stress
- cholesterol biosynthetic process
- erythrocyte maturation
- glucose 6-phosphate metabolic process
- glucose metabolic process
- glutathione metabolic process
- lipid metabolic process
- NADP+ metabolic process
- negative regulation of cell growth involved in cardiac muscle cell development
- negative regulation of reactive oxygen species metabolic process
- pentose biosynthetic process
- pentose-phosphate shunt
- pentose-phosphate shunt, oxidative branch
- positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel
- regulation of neuron apoptotic process
- response to ethanol
- response to food
- response to iron(III) ion
- substantia nigra development
- ribose phosphate biosynthetic process
Molecular functions
- D-glucose binding
- glucose-6-phosphate dehydrogenase activity
- identical protein binding
- NADP binding
- protein homodimerization activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Glucose-6-phosphate dehydrogenase
- Glucose-6-phosphate dehydrogenase, active site
- Glucose-6-phosphate dehydrogenase, NAD-binding
- Glucose-6-phosphate dehydrogenase, C-terminal
- NAD(P)-binding domain superfamily
- Glucose-6-phosphate dehydrogenase, NAD binding domain
- Glucose-6-phosphate dehydrogenase, C-terminal domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of G6PD in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads G6PD as an antibody target. Whether an autoantibody or antibody against G6PD could matter depends on whether native G6PD is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
G6PD is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label G6PD as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...